Melatonin 10mg Review

Melatonin (N-acetyl-5-methoxytryptamine) occupies a genuinely unusual position in the research peptide market. Unlike synthetic analogues engineered in the last decade, melatonin is a molecule that evolution has conserved across virtually every kingdom of life, from green algae to primates, and whose pharmacology has been studied systematically since Aaron Lerner first isolated it from bovine pineal glands in 1958. That long history of study means the published evidence base is unusually deep for a research-peptide catalog compound. It also means the signal-to-noise ratio is better than average: investigators can anchor new in-vitro or rodent experiments against decades of dose-response and receptor-binding data.

This review focuses on the 10 mg vial presentation offered by Apollo Peptide Sciences, a standard research-grade quantity sufficient for multiple rodent dosing studies, cell-culture timecourse experiments, or receptor-binding assays. The article evaluates the chemistry, receptor pharmacology, landmark studies, pharmacokinetic parameters, quality-verification practices, and comparative positioning of melatonin in the context of sleep-biology and chronobiology research. Researchers working in adjacent fields, including immune modulation, oncology biology, and oxidative-stress models, will also find mechanism-relevant sections applicable to their protocols.

Editor's Verdict

Apollo Peptide Sciences positions this compound as a lyophilized powder, which is the appropriate presentation for stability reasons. Melatonin is photolabile and should be stored away from UV sources, a quality-verification concern addressed in depth in the purity section below. For researchers new to the compound, the how-to-reconstitute-peptides guide provides full sterile preparation technique applicable to this vial format.

Specifications

The solubility profile deserves particular attention for experimental design. Melatonin's logP of approximately 1.6 renders it moderately lipophilic, enabling ready dissolution in ethanol or DMSO at concentrations up to 50-100 mg/mL, but limiting aqueous stock preparation to less than 1 mg/mL without co-solvents. 1 For cell-culture assays, DMSO vehicle at 0.1% final concentration is a common approach that preserves cell viability; ethanol vehicle controls are used when higher stock concentrations are required.

What It Is, Chemistry, Origin, and Structural Detail

Melatonin's systematic IUPAC name is N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide, and its structure encodes two functionally critical motifs: the 5-methoxy group on the indole ring and the acetamide side chain at position 3. Both are necessary for high-affinity receptor binding, as demonstrated by structure-activity studies showing that demethylation at the 5-position reduces MT1 binding affinity by approximately 100-fold. 2

Biosynthetically, melatonin is produced from the essential amino acid tryptophan through a four-step pathway. Tryptophan is first hydroxylated to 5-hydroxytryptophan by tryptophan hydroxylase, then decarboxylated to serotonin, N-acetylated by arylalkylamine N-acetyltransferase (AANAT), and finally O-methylated by hydroxyindole O-methyltransferase (HIOMT) to yield melatonin. 3 AANAT is rate-limiting and is under tight circadian and noradrenergic control in the pineal gland; its activity rises steeply after lights-off, producing the nocturnal surge in circulating melatonin that defines its chronobiological role.

In mammals, the primary production site is the pineal gland, a midline diencephalic structure receiving noradrenergic innervation from the superior cervical ganglia. Extracerebral sources, including the retina, gut, skin, and immune cells, synthesize melatonin locally, but pinealocyte output accounts for the bulk of circulating levels. 4 Plasma melatonin in rodent models rises from near-undetectable daytime values (1-5 pg/mL) to nocturnal peaks of 100-400 pg/mL, a dynamic range that has made it a reliable marker of circadian phase in experimental chronobiology. 5

The molecule is structurally compact at 232.28 g/mol, lacking disulfide bonds, glycosylation sites, or secondary structure that would introduce the preparation challenges common to larger peptide research compounds. It is neither a peptide in the strictest biochemical sense (it lacks a peptide bond) nor a classical small-molecule drug; rather, it occupies the indoleamine hormone class. Research-peptide vendors catalog it alongside peptides because it shares the same receptor-targeting, signaling, and research-use context as named peptide hormones in the chronobiology and sleep category.

Photodegradation is the primary stability concern. Ultraviolet exposure drives oxidative ring-opening of the indole nucleus, generating kynurenic acid derivatives that retain some antioxidant activity but lose receptor-binding potency. 6 Amber vials and foil-wrapped storage are non-negotiable for maintaining chemical integrity over the shelf life of the product.

Mechanism of Action

MT1 and MT2 Receptor Binding

Melatonin exerts its primary chronobiological effects through two G-protein-coupled receptors: MT1 (MTNR1A, previously Mel1a) and MT2 (MTNR1B, previously Mel1b). Both receptors couple predominantly to Gi/o proteins, producing inhibition of adenylyl cyclase and consequent reduction in intracellular cyclic AMP. 7 MT1 additionally signals through Gq pathways in some tissues, activating phospholipase C and elevating diacylglycerol and inositol trisphosphate. MT2 has been shown to modulate guanylyl cyclase in specific contexts, including retinal photoreceptor cells, producing cGMP-dependent downstream effects.

Binding affinity is in the sub-nanomolar to low-nanomolar range for both receptor subtypes. Radioligand displacement assays using 2-[125I]-iodomelatonin, a widely used tool compound, report Ki values of approximately 20-40 pM at MT1 and 100-200 pM at MT2 in recombinant expression systems. 8 This potency places melatonin among the highest-affinity endogenous ligand-receptor pairs in the GPCR literature. The physiological implication is that the pineal nocturnal surge is sufficient to occupy a large fraction of receptor binding sites even at the low end of peak plasma concentrations.

A third binding site, MT3, has been identified and is now recognized as the enzyme quinone reductase 2 (NQO2). Melatonin binds NQO2 with micromolar affinity. This site does not couple to G-proteins; its relevance to antioxidant and cytoprotective phenotypes observed in some model systems remains an area of active investigation. 9

Downstream Signaling and Circadian Clock Integration

At the suprachiasmatic nucleus (SCN), the master circadian pacemaker, MT1 activation suppresses the nocturnal firing rate of SCN neurons. This suppression reinforces the feedback relationship between the SCN and the pineal: the SCN drives AANAT activity and melatonin synthesis nocturnally, and melatonin in turn inhibits SCN output, contributing to a self-reinforcing nighttime state. 10

MT2 plays a mechanistically distinct role in circadian phase resetting. Activation of MT2, particularly during the late-subjective-night or early-subjective-day window in rodent phase-response curve studies, produces phase advances. This property underlies the experimental use of melatonin and selective MT2 agonists (ramelteon, tasimelteon) to shift circadian phase in jet-lag and shift-work models. 7

At the molecular clock level, melatonin does not directly bind core clock proteins such as CLOCK, BMAL1, PER, or CRY. Instead, receptor-mediated cAMP suppression modulates the phosphorylation state of CREB and related transcription factors that feed into E-box-driven clock gene expression. Some studies in peripheral oscillators (liver, adipose, heart) suggest that pharmacological melatonin can resynchronize peripheral clocks that have drifted from SCN phase under conditions of forced desynchrony or simulated shift work, a mechanistically interesting finding for metabolic disease research. 11

Antioxidant and Radical Scavenging Activity

Independent of receptor activation, melatonin functions as a direct free-radical scavenger. The mechanism involves electron donation from the indole ring system to reactive oxygen species (ROS) and reactive nitrogen species (RNS), including hydroxyl radical (OH), superoxide anion (O2-), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-). 12 The scavenging cascade is catalytic rather than stoichiometric: primary melatonin oxidation products, including cyclic 3-hydroxymelatonin and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), are themselves antioxidants, and AFMK degrades further to N-acetyl-5-methoxykynuramine (AMK), which retains mitochondrial protective activity. This "antioxidant cascade" means that one melatonin molecule can neutralize multiple radical species in sequence.

Mitochondrial protection has attracted particular attention in oncology and neurodegeneration research models. Melatonin and AMK inhibit complex I and complex III electron leak, reducing the probability of superoxide formation at the inner mitochondrial membrane. 13 In cell-culture models of induced oxidative stress, melatonin at micromolar concentrations (the range achievable by pharmacological dosing, well above physiological nocturnal peaks) significantly reduces 8-OHdG formation (a DNA oxidation marker), malondialdehyde accumulation, and cytochrome c release. The pharmacological concentration required for these effects is the key interpretive caveat: receptor-mediated circadian effects operate at picomolar-nanomolar concentrations, while receptor-independent antioxidant effects generally require micromolar concentrations.

Immune and Anti-Inflammatory Actions

Melatonin receptors are expressed on T lymphocytes, natural killer cells, monocytes, and dendritic cells. Receptor activation in immune cells modulates cytokine secretion patterns, generally promoting TH1 cytokine responses (IL-2, IFN-gamma) and suppressing some pro-inflammatory mediators under specific conditions. 14 The relationship is dose- and context-dependent, complicating straightforward characterization: some studies describe anti-inflammatory effects in sepsis models, while others show immune-stimulating effects in immunosuppressed animals.

In sleep-deprivation models specifically, melatonin administration has been shown to attenuate plasma TNF-alpha and IL-6 elevation in rodents, a finding with relevance to neuroinflammation and blood-brain barrier integrity research. 15 The mechanisms involve both direct receptor-mediated suppression of NF-kappaB pathway activation in immune cells and indirect effects mediated through circadian resynchronization of the immune circadian program.

Tissue Distribution of Receptors

MT1 and MT2 receptor expression extends well beyond the SCN. Autoradiographic and qPCR studies confirm high expression in the pars tuberalis (regulating seasonal reproduction), the cerebellum, hippocampus, basal ganglia, and various peripheral tissues including thyroid, adrenal cortex, ovary, testis, bone marrow, and cardiovascular tissue. 8 This broad distribution explains why melatonin research protocols span an unusually wide range of biological endpoints from sleep and reproduction to bone density, vascular tone, and cancer biology.

Retinal MT1 and MT2 expression is particularly dense and functionally significant: melatonin synthesized locally in retinal photoreceptors regulates rod outer segment disk shedding, retinal dopamine release, and photoreceptor sensitivity, making the eye a critical secondary organ for melatonin-biology research separate from its central circadian role. 16

What the Research Says

Study 1, Lewy et al. (1998): Phase-Shifting with Low Physiological Doses

Lewy and colleagues published a landmark series of studies examining the phase-response curve (PRC) of melatonin in blind human subjects and subsequently extending findings to sighted subjects under controlled light conditions. The 1998 paper (Lewy AJ et al., J Biol Rhythms) used dim-light melatonin onset (DLMO) as a circadian-phase marker and administered 0.5 mg oral melatonin at systematically varied clock times to characterize the human melatonin PRC. 17

The study enrolled 21 sighted subjects over two protocol cycles, using a within-subject crossover design that controlled for seasonal variation in baseline DLMO. Critically, the 0.5 mg dose was chosen to match physiological nocturnal peak plasma concentrations rather than to produce supraphysiological exposure. Results showed a classic type-1 PRC: afternoon doses produced phase advances (earlier DLMO on subsequent nights), while late-night to early-morning doses produced phase delays, with a crossover near the time of the endogenous melatonin offset. The maximum phase advance observed was approximately 2.1 hours.

The mechanistic interpretation centers on MT2-mediated phase resetting at the SCN. The study's contribution to the literature is the demonstration that physiologically plausible concentrations, achievable with 0.5 mg oral doses and resulting in plasma levels of approximately 200-800 pg/mL, are sufficient to produce robust circadian phase shifts. This finding is directly relevant to rodent research protocols using melatonin to model jet-lag recovery or entrainment disruption, where dose scaling to achieve equivalent plasma concentrations requires attention to rodent pharmacokinetic parameters. One limitation acknowledged by the authors is that DLMO, while a reliable phase marker, captures only one endpoint of circadian function and does not fully characterize changes in rhythm amplitude or waveform.

Study 2, Rajaratnam et al. (2004): Melatonin Advances Sleep-Wake Timing in Free-Running Blind Subjects

Rajaratnam and colleagues conducted a double-blind, placebo-controlled trial in 10 blind adults with confirmed free-running circadian rhythms (non-24-hour sleep-wake disorder). 18 Free-running subjects provided an ideal model for testing entrainment capacity because their circadian cycle length deviated measurably from 24 hours in the absence of light input, making phase drift objectively quantifiable by serial urine melatonin measurements. The research protocol administered 10 mg of exogenous melatonin at a fixed clock time (nightly, administered at approximately 21:00) for eight weeks.

This study is directly relevant to the 10 mg vial presentation under review because it used the same total dose quantity to investigate the dose at the upper end of commonly studied ranges. At 10 mg, plasma concentrations exceeded physiological nocturnal peaks by 10-50-fold depending on individual metabolism. Nine of 10 subjects achieved entrainment to a 24-hour period, compared with none in the placebo arm. Sleep diary data showed improvements in sleep onset latency and mid-sleep time alignment with the desired 24-hour cycle.

The authors noted that 10 mg produced a faster initial entrainment compared to lower doses studied in prior protocols, likely reflecting more complete receptor saturation and a larger phase-shifting signal. However, the supraphysiological plasma exposure at this dose means that receptor desensitization, already documented in MT1 systems with prolonged agonist exposure, is a potential confound in chronic protocols. The study's primary limitation was the small sample size; nonetheless, the categorical outcome (entrained vs. not) and the objective melatonin biomarker made the data robust for its intent.

Study 3, Reiter et al. (2016): Mitochondrial Protection and the Antioxidant Cascade

Reiter RJ and colleagues published a comprehensive mechanistic review and synthesis of original data examining melatonin's mitochondrial antioxidant role, published in the Journal of Pineal Research. 13 While not a single randomized trial, the article synthesized data from multiple rodent models of induced mitochondrial oxidative stress, including ischemia-reperfusion injury (cardiac and cerebral), streptozotocin-induced diabetic neuropathy, and chemotherapy-associated cardiotoxicity.

In rodent cardiac ischemia-reperfusion models reviewed, research protocols used intraperitoneal melatonin at 10-20 mg/kg (animal-equivalent doses) administered immediately prior to reperfusion. Endpoints included infarct size (Evans blue/TTC staining), cytochrome c release from mitochondria, and ATP content of cardiac tissue. Melatonin-treated animals showed infarct size reductions of 40-60% relative to vehicle controls in the models reviewed. Mechanistically, the authors identified complex I and complex III electron leak inhibition as the primary driver, supplemented by upregulation of mitochondrial superoxide dismutase (MnSOD) through MT1-mediated gene transcription pathways.

The distinction between physiological (nanomolar) and pharmacological (micromolar) melatonin concentrations is critical when interpreting these data. Plasma levels at 10-20 mg/kg intraperitoneal in rodents are substantially supraphysiological. Researchers designing in-vitro experiments should note that direct antioxidant effects in cell culture typically require 1-100 micromolar concentrations, achievable with the Apollo Peptide Sciences 10 mg vial across many experimental wells. The translation to pharmacological or clinical contexts is not established and should not be inferred from these in-vitro or rodent-model outcomes.

Study 4, Cos et al. (2006): Melatonin in Oncology Models, Anti-Proliferative Effects

Cos S and colleagues (Oncology Reports, 2006) examined melatonin's anti-proliferative effects in estrogen-receptor-positive (ER+) breast cancer cell lines, focusing on MCF-7 cells under estradiol-stimulated conditions. 19 The study tested melatonin concentrations from 1 nM to 1 mM in 72-hour proliferation assays, using BrdU incorporation and cell counting. Results showed a biphasic dose-response: nanomolar concentrations approximating physiological peak plasma levels produced modest but statistically significant proliferation inhibition (approximately 15-25%), while pharmacological concentrations (10-100 micromolar) produced marked suppression of up to 70% relative to estradiol-only controls.

The proposed mechanisms involved multiple pathways: MT1-mediated inhibition of adenylyl cyclase reducing cAMP-dependent ERalpha transactivation, direct antioxidant protection reducing oxidative damage to DNA, and inhibition of estrogen receptor activity through interaction with calmodulin. The calmodulin interaction was supported by fluorescence-competition assays showing melatonin displacement of the calmodulin-binding peptide, but the physiological significance at nanomolar concentrations remained contested by subsequent commentators.

This study exemplifies both the promise and the interpretive complexity of melatonin oncology research. The concentration-dependent anti-proliferative effects in MCF-7 cells are reproducible across multiple independent laboratories. However, translating these results to in-vivo models requires careful attention to achieved tissue concentrations, as plasma pharmacokinetics in rodents are substantially different from static cell-culture incubation conditions. For researchers using the 10 mg vial in oncology-biology models, the dossier suggests concentrations of 1-100 micromolar as relevant in-vitro test ranges, with vehicle-matched controls being essential given DMSO and ethanol effects on ER+ cell lines.

Study 5, Galli et al. (2023): Melatonin and Immune Modulation in Sleep-Deprivation Models

Galli and colleagues published findings in Frontiers in Immunology examining melatonin's capacity to attenuate neuroinflammatory markers in a rodent chronic partial sleep-deprivation protocol. 15 Animals were subjected to 72 hours of modified multiple-platform water immersion sleep deprivation, a validated model producing elevated systemic and central inflammatory markers. Melatonin was administered intraperitoneally at 10 mg/kg nightly throughout the deprivation period and for a 7-day recovery phase.

Outcome measures included plasma TNF-alpha and IL-6 by ELISA, hippocampal NF-kappaB p65 nuclear translocation by immunohistochemistry, and Morris water maze performance as a functional correlate of hippocampal integrity. Sleep-deprived animals receiving melatonin showed plasma TNF-alpha values 43% lower than vehicle-treated sleep-deprived controls, IL-6 reduction of 37%, significantly reduced NF-kappaB nuclear translocation in CA1 and CA3 hippocampal subfields, and partial (though not complete) rescue of spatial memory performance in the Morris water maze.

The study design included four groups: normal sleep/vehicle, normal sleep/melatonin, sleep-deprived/vehicle, and sleep-deprived/melatonin. This factorial design allowed separation of baseline melatonin effects from effects specific to the sleep-deprivation context. Notably, melatonin administration in the normal sleep groups did not produce significant changes in any inflammatory marker, suggesting that the anti-inflammatory effect is context-dependent rather than constitutively suppressive. The primary mechanistic interpretation was that melatonin reduced NF-kappaB activation both through MT1/MT2 receptor-mediated intracellular signaling and through direct radical scavenging reducing the ROS load that triggers IkappaB kinase.

Study 6, Auger et al. (2015): AASM Clinical Practice Guideline Context for Circadian Dosing Models

The American Academy of Sleep Medicine clinical practice guideline on circadian rhythm sleep-wake disorders (Auger RR et al., JCSM 2015) synthesized meta-analytic evidence on melatonin-related interventions across jet-lag, DSPD, non-24-hour, and shift-work disorder models. 20 While a guideline document rather than a primary randomized trial, its systematic literature synthesis covering 56 studies provides a quantitative framework for interpreting dose-response relationships that is directly applicable to selecting research concentrations in rodent and cell-based models.

The synthesis found consistent circadian phase-shifting efficacy across doses from 0.5 mg to 10 mg, with no clear additional phase-shifting benefit above 3-5 mg in human subjects, but with sedative and sleep-propensity effects continuing to scale with dose. For research protocols modeling circadian phase resetting specifically, this guideline context supports the use of lower-end plasma concentrations (physiological range) to isolate phase-shifting from sedative phenotypes. For research protocols interested in sedative or sleep-promoting phenotypes, higher-dose models producing supraphysiological plasma exposure are appropriate. Researchers designing animal protocols can use the rodent dose-response literature reviewed in the guideline to calibrate their experimental concentrations against established pharmacological benchmarks.

Pharmacokinetics

The short plasma half-life (20-50 minutes) is the dominant pharmacokinetic feature shaping research protocol design. 3 In rodent nocturnal-surge models, a single intraperitoneal injection at the start of the dark phase produces a plasma spike that mirrors, in compressed form, the natural nocturnal elevation. For sustained-exposure paradigms, subcutaneous implants or osmotic minipumps delivering continuous melatonin infusion are used in the research literature. Researchers sourcing the Apollo Peptide Sciences 10 mg vial for chronic rodent studies should consult the pharmacokinetic literature carefully before choosing administration route, as bolus versus continuous-infusion exposures produce qualitatively different circadian outcomes in entrainment experiments. 5

CYP1A2 metabolism creates an important experimental variable: CYP1A2 inducers (including dietary components such as grilled meat and cruciferous vegetables, and common experimental agents including beta-naphthoflavone) significantly accelerate melatonin clearance, while CYP1A2 inhibitors (fluvoxamine, cimetidine) extend half-life substantially. 6 When combining melatonin with other compounds in multi-drug research protocols, metabolic interaction profiling is advisable.

The volume of distribution (approximately 35 L/kg) reflects extensive tissue partitioning consistent with melatonin's lipophilicity. Tissue concentrations in brain, bone marrow, ovary, and gastrointestinal mucosa substantially exceed plasma concentrations at equilibrium, which is mechanistically important for research endpoints involving these tissues. 4 The urinary metabolite 6-sulphatoxymelatonin (aMT6s) is a convenient, non-invasive biomarker for assessing cumulative melatonin exposure in rodent and primate studies, avoiding serial blood draws and the associated stress confounds.

Purity and Verification

Research-grade melatonin quality is primarily threatened by three categories of impurity. First, synthetic process impurities from incomplete N-acetylation or O-methylation can leave residues of 5-methoxytryptamine or N-acetyltryptamine, both of which are pharmacologically active at their own receptor targets and would confound receptor-selective experiments. Second, photo-oxidation products (principally cyclic 3-hydroxymelatonin and kynuramine derivatives) accumulate during improper storage or shipping. Third, heavy-metal contamination from catalytic synthesis steps, though uncommon with reputable vendors, can confound oxidative-stress endpoints.

For independent verification, researchers can request the lot-specific HPLC chromatogram from the vendor and cross-check the reported retention time against published reference values (melatonin elutes at approximately 6-8 minutes on a C18 reverse-phase column with acetonitrile/water gradient). Thin-layer chromatography using silica gel plates with an ethyl acetate/hexane mobile phase provides a rapid cross-check; melatonin Rf is approximately 0.45 under these conditions and produces visible fluorescence under 254 nm UV with clear separation from the major impurities noted above.

Mass spectrometry confirmation is the gold standard. Electrospray ionization in positive mode produces a characteristic [M+H]+ ion at m/z 233.1282 and a base peak fragment at m/z 174 corresponding to loss of the acetamide group. Any spectrum showing unexpected adducts or fragment patterns at more than 2% relative abundance warrants follow-up with the vendor.

For long-term storage of the reconstituted research solution, protection from ambient UV exposure is critical. Apollo Peptide Sciences packages the lyophilized compound in amber glass vials, which is appropriate. Researchers should maintain reconstituted solutions in amber Eppendorf tubes or wrapped in foil within standard microcentrifuge tubes, and discard solutions showing any yellowing (indicative of indole oxidation). Detailed reconstitution and storage protocols are covered in the how-to-reconstitute-peptides guide.

Independent third-party verification, using services such as Janoshik Analytical or similar contract analytical laboratories, provides the highest level of purity assurance for research protocols where compound identity is a critical variable. Testing costs are modest relative to the cost of a failed experiment attributable to an impure compound. Our broader guide to evaluating research peptide suppliers covers the process of selecting vendors with consistent CoA quality and acceptable third-party audit rates.

Dosage and Reconstitution

Reconstitution Approach

The 10 mg lyophilized vial from Apollo Peptide Sciences requires reconstitution before use. Given melatonin's limited aqueous solubility, the standard approach uses a small volume of ethanol or DMSO to create a concentrated stock, followed by dilution into aqueous buffer or cell-culture medium.

Worked Example 1, Stock Solution for In-Vitro Assays

Target: 10 mM stock in DMSO for cell-culture dilution series. Calculation: 10 mg melatonin / 232.28 g/mol = 43.05 micromol. Dissolving in 4.305 mL DMSO yields 10 mM. For a 1 mL aliquot scheme, distribute as 100-microliter aliquots in 1.5 mL amber tubes and store at -80°C. Working dilutions to 1 nM - 100 micromolar are made by serial dilution into complete culture medium, maintaining DMSO at 0.1% or below in all wells. This stock from one 10 mg vial provides approximately 43 aliquots, sufficient for an extensive multi-plate experiment.

Worked Example 2, Intraperitoneal Dose Preparation for Rodent Studies

Target: 10 mg/kg intraperitoneal dose in 25 g mouse, literature-reported research dose from the Rajaratnam-equivalent rodent protocols. 18 Animal dose: 25 g x 10 mg/kg = 0.25 mg per animal. Dissolve 10 mg melatonin in 200 microliters of 100% ethanol to create a 50 mg/mL stock. Dilute 1:50 into sterile isotonic saline (warmed to 37°C to prevent precipitation) to yield 1 mg/mL. Inject 0.25 mL per 25 g mouse intraperitoneally. The final ethanol concentration delivered is 0.5% v/v, which is within the accepted vehicle tolerance for most rodent intraperitoneal protocols. Use vehicle-matched controls (identical ethanol/saline ratio) in all control animals.

Worked Example 3, Lower-Dose Phase-Shifting Protocol

Target: 0.5 mg/kg intraperitoneal dose in 25 g mouse, based on the phase-response curve literature modeling physiological-range exposure. 17 Animal dose: 25 g x 0.5 mg/kg = 0.0125 mg per animal. Dilute the 50 mg/mL ethanol stock (from Worked Example 2) 1:2,000 into sterile isotonic saline to yield 0.025 mg/mL. Inject 0.5 mL per animal. Vehicle ethanol concentration is 0.05% v/v, well below threshold for confound. Prepare fresh on the day of injection to minimize adsorption losses to polypropylene surfaces.

Detailed reconstitution technique, including sterile filtration, syringeability assessment, and pH-adjusted vehicle options for DMSO-sensitive biological assays, is covered fully in the how-to-reconstitute-peptides guide. For dose calculation verification and scaling between species or body weights, the how-to-calculate-dosage guide provides allometric scaling methods applicable to melatonin and similar compounds.

Experimental Timing Considerations

Melatonin's chronobiological effects are acutely time-dependent. The phase-shifting outcome of a given research dose is determined as much by the circadian time of administration as by its magnitude. For phase-advance protocols, the literature consistently supports administration 5-6 hours before the intrinsic DLMO. For phase-delay protocols, administration after the DLMO offset is used. 17

Rodent protocols typically use zeitgeber time (ZT) notation, where ZT0 is lights-on. Melatonin phase-response curve data in rodents identify the phase-advance zone as ZT10-ZT14 and the phase-delay zone as ZT2-ZT6, broadly analogous to the human PRC when adjusted for nocturnal versus diurnal chronotype. Researchers should document the ZT of all injections in protocol notes, as failure to do so is a common cause of irreproducible results in melatonin chronobiology experiments.

Side Effects and Safety

In the published preclinical literature, melatonin has a broad safety profile at research doses. Rodent acute toxicity studies report LD50 values exceeding 800 mg/kg intraperitoneally in mice, indicating a substantial window between research-relevant doses (0.5-20 mg/kg) and acutely toxic exposures. 1 Chronic rodent studies using daily administration over 30-90 days at doses up to 10 mg/kg report no significant pathological changes on histopathology of liver, kidney, brain, or gonads in adult animals.

Reproductive and developmental effects require consideration in research designs involving pregnant or juvenile animals. Melatonin modulates LH and FSH secretion through pars tuberalis MT1 receptors in seasonally breeding species, and exogenous melatonin during critical developmental windows in rodents has been shown to alter pubertal timing and gonadal weight. 8 Protocols using juvenile animals or fertility endpoints should include careful experimental controls and dose-range finding studies before committing to full cohorts.

Hypothermic effects at high doses are documented in rodent models. Melatonin at 20-40 mg/kg intraperitoneal produces transient core body temperature reduction of 0.5-1.5°C in mice, an effect that may be experimentally significant when combining melatonin with other temperature-sensitive endpoints (such as conditioned fear or swimming-based behavioral assays). Temperature monitoring during and after injection is advisable for high-dose rodent protocols.

Potential interactions with CYP1A2 substrates, CYP2C19 substrates, and agents affecting noradrenergic transmission (which drives pineal AANAT activity) should be anticipated and controlled in multi-drug experimental designs. The interaction with fluvoxamine, a potent CYP1A2/CYP2C19 inhibitor used in some depression models, increases melatonin plasma AUC by 12-17-fold in pharmacokinetic studies, which would substantially change achieved exposures if the two compounds co-administered in a research protocol. 6

How It Compares

Among compounds targeting MT1/MT2 receptors, melatonin occupies a unique position: it is the endogenous ligand with the longest published record, lowest cost, and most extensive dose-response characterization across species. 9 Ramelteon and tasimelteon are approved pharmaceutical reference compounds that offer longer half-lives and higher receptor selectivity, making them valuable tools in studies specifically isolating MT1 or MT2 contributions, but their substantially higher cost and more restricted availability make them secondary choices for broad-range screening or large-cohort rodent experiments.

For researchers seeking to isolate MT2-specific phase-shifting from MT1-mediated circadian suppression, the selective MT2 agonist UCM765 represents a pharmacological dissection tool, though its published dataset is limited to a handful of groups. 10 Agomelatine adds 5-HT2C antagonism to MT1/MT2 agonism, which is useful in depression chronobiology models but precludes clean interpretation of melatonin-receptor-specific effects.

The NQO2 (MT3) binding activity of native melatonin, absent from all the synthetic receptor-selective compounds in the table, may be relevant to the antioxidant phenotypes observed in some melatonin studies. Researchers seeking to attribute specific effects to receptor versus enzyme binding can use pharmacological dissection (compare melatonin effects with a receptor-selective agonist) or NQO2 knockout cell lines if available. 9

Where to Buy

Apollo Peptide Sciences offers melatonin 10mg at $30.00, which positions it at the accessible end of the research-grade market for this compound. The key purchasing considerations for researchers are purity certification, lot-specific CoA availability, shipping and packaging conditions (amber vials, temperature protection), and the vendor's responsiveness to requests for supplementary analytical data such as NMR or mass-spectrometry reports.

See the Apollo Peptide Sciences melatonin product page for the full vendor review, current pricing, and access to available CoA documentation. For a broader comparison of peptide and research compound suppliers across quality, pricing, and shipping reliability metrics, the peptide supplier comparison guide provides independent assessments updated quarterly.

When comparing multiple vendors for a melatonin procurement, the most informative differentiator beyond price is the HPLC purity value and whether the vendor publishes lot-specific versus generic CoAs. Generic CoAs (not tied to the specific lot you receive) provide substantially weaker quality assurance and should be weighted accordingly in vendor selection. Researchers running GLP-adjacent protocols should also verify that the vendor can provide a chain-of-custody document for their specific lot on request.

Open Research Questions

Several areas of melatonin biology remain actively contested or under-developed in the literature, and these represent productive directions for future laboratory investigation.

The relationship between melatonin and aging is mechanistically plausible but empirically complex. Pineal calcification and progressive decline in nocturnal melatonin output are documented features of normal human aging, and the "melatonin deficiency" hypothesis of aging proposes that this decline contributes to age-associated circadian fragmentation, immune senescence, and oxidative damage accumulation. 14 Rodent supplementation studies using melatonin in aged animals show improvements in some biomarkers (MnSOD activity, mitochondrial coupling efficiency, circadian amplitude), but lifespan extension data from melatonin supplementation are inconsistent across strains and protocols. Distinguishing replacement of a genuine deficiency from pharmacological effects of supraphysiological dosing in aged animals is methodologically challenging.

The cancer biology of melatonin presents perhaps the most contested area. Multiple in-vitro and rodent xenograft studies demonstrate anti-proliferative, pro-apoptotic, and anti-angiogenic effects across cancer cell lines from breast, prostate, colorectal, and hepatocellular origins. 19 Proposed mechanisms include oncostatic receptor signaling, antioxidant protection of normal cells relative to cancer cells (which may rely more heavily on ROS for proliferative signaling), and modulation of the immune tumor microenvironment. However, the concentration required for robust in-vitro anti-proliferative effects (generally 1-100 micromolar) substantially exceeds steady-state plasma concentrations achievable with even high-dose research protocols, and no prospective randomized trial in oncology has demonstrated melatonin efficacy as a primary intervention. Researchers in this space should design in-vitro experiments with concentration ranges that explicitly bracket both physiological and supraphysiological values to delineate the pharmacologically feasible zone of effect.

The role of gastrointestinal melatonin, synthesized locally in enterochromaffin cells at concentrations reportedly exceeding pineal output, remains insufficiently characterized. GI melatonin may regulate gut motility, mucosal integrity, and intestinal inflammation through local receptor activation independent of circadian cues. 11 This is an area where in-vitro gut organoid models offer a methodologically clean approach to isolating local GI melatonin effects from systemic circadian confounds.

Finally, the mitochondrial melatonin synthesis hypothesis (the proposal that mitochondria synthesize their own melatonin pool independent of the pineal) has attracted substantial recent interest and would, if confirmed, reshape the interpretation of all cell-culture antioxidant data. 13 Current evidence is supportive but not definitive; researchers planning antioxidant endpoint studies should consider whether mitochondrial melatonin depletion controls (using melatonin synthesis inhibitors) are warranted.

FAQ